Korean Journal of Radiology

The Korean Society of Radiology (대한영상의학회)
권호 표지
DOI QR코드

DOI QR Code

In-Vivo Proton Magnetic Resonance Spectroscopy of 2-Hydroxyglutarate in Isocitrate Dehydrogenase-Mutated Gliomas: A Technical Review for Neuroradiologists

  • Kim, Hyeonjin (Department of Radiology, Seoul National University Hospital) ;
  • Kim, Sungjin (Department of Radiology, Seoul National University Hospital) ;
  • Lee, Hyeong Hun (Department of Biomedical Sciences, Seoul National University) ;
  • Heo, Hwon (Department of Biomedical Sciences, Seoul National University)
  • Received : 2016.02.03
  • Accepted : 2016.06.02
  • Published : 2016.09.01
⟨ Previous Next ⟩

Abstract

The diagnostic and prognostic potential of an onco-metabolite, 2-hydroxyglutarate (2HG) as a proton magnetic resonance spectroscopy (1H-MRS) detectable biomarker of the isocitrate dehydrogenase (IDH)-mutated (IDH-MT) gliomas has drawn attention of neuroradiologists recently. However, due to severe spectral overlap with background signals, quantification of 2HG can be very challenging. In this technical review for neuroradiologists, first, the biochemistry of 2HG and its significance in the diagnosis of IDH-MT gliomas are summarized. Secondly, various 1H-MRS methods used in the previous studies are outlined. Finally, wereview previous in vivo studies, and discuss the current status of 1H-MRS in the diagnosis of IDH-MT gliomas.

Keywords

Acknowledgement

Supported by : Ministry for Health, Welfare & Family Affairs, Seoul National University College of Medicine

References

  1. Law M, Yang S, Wang H, Babb JS, Johnson G, Cha S, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 2003;24:1989-1998
  2. Moller-Hartmann W, Herminghaus S, Krings T, Marquardt G, Lanfermann H, Pilatus U, et al. Clinical application of proton magnetic resonance spectroscopy in the diagnosis of intracranial mass lesions. Neuroradiology 2002;44:371-381 https://doi.org/10.1007/s00234-001-0760-0
  3. Herholz K, Heindel W, Luyten PR, denHollander JA, Pietrzyk U, Voges J, et al. In vivo imaging of glucose consumption and lactate concentration in human gliomas. Ann Neurol 1992;31:319-327 https://doi.org/10.1002/ana.410310315
  4. Rock JP, Scarpace L, Hearshen D, Gutierrez J, Fisher JL, Rosenblum M, et al. Associations among magnetic resonance spectroscopy, apparent diffusion coefficients, and image-guided histopathology with special attention to radiation necrosis. Neurosurgery 2004;54:1111-1117; discussion 1117-1119 https://doi.org/10.1227/01.NEU.0000119328.56431.A7
  5. Verma N, Cowperthwaite MC, Burnett MG, Markey MK. Differentiating tumor recurrence from treatment necrosis: a review of neuro-oncologic imaging strategies. Neuro Oncol 2013;15:515-534 https://doi.org/10.1093/neuonc/nos307
  6. Bluml S, Panigrahy A, Laskov M, Dhall G, Krieger MD, Nelson MD, et al. Elevated citrate in pediatric astrocytomas with malignant progression. Neuro Oncol 2011;13:1107-1117 https://doi.org/10.1093/neuonc/nor087
  7. Howe FA, Barton SJ, Cudlip SA, Stubbs M, Saunders DE, Murphy M, et al. Metabolic profiles of human brain tumors using quantitative in vivo 1H magnetic resonance spectroscopy. Magn Reson Med 2003;49:223-232 https://doi.org/10.1002/mrm.10367
  8. Majos C, Alonso J, Aguilera C, Serrallonga M, Perez-Martin J, Acebes JJ, et al. Proton magnetic resonance spectroscopy ((1) H MRS) of human brain tumours: assessment of differences between tumour types and its applicability in brain tumour categorization. Eur Radiol 2003;13:582-591
  9. Zonari P, Baraldi P, Crisi G. Multimodal MRI in the characterization of glial neoplasms: the combined role of single-voxel MR spectroscopy, diffusion imaging and echoplanar perfusion imaging. Neuroradiology 2007;49:795-803 https://doi.org/10.1007/s00234-007-0253-x
  10. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321:1807-1812 https://doi.org/10.1126/science.1164382
  11. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360:765-773 https://doi.org/10.1056/NEJMoa0808710
  12. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009;462:739-744 https://doi.org/10.1038/nature08617
  13. Andronesi OC, Rapalino O, Gerstner E, Chi A, Batchelor TT, Cahill DP, et al. Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate. J Clin Invest 2013;123:3659-3663 https://doi.org/10.1172/JCI67229
  14. Pope WB, Prins RM, Albert Thomas M, Nagarajan R, Yen KE, Bittinger MA, et al. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. J Neurooncol 2012;107:197-205 https://doi.org/10.1007/s11060-011-0737-8
  15. Andronesi OC, Kim GS, Gerstner E, Batchelor T, Tzika AA, Fantin VR, et al. Detection of 2-hydroxyglutarate in IDHmutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. Sci Transl Med 2012;4:116ra4
  16. Choi C, Ganji SK, DeBerardinis RJ, Hatanpaa KJ, Rakheja D, Kovacs Z, et al. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med 2012;18:624-629 https://doi.org/10.1038/nm.2682
  17. Choi C, Ganji S, Hulsey K, Madan A, Kovacs Z, Dimitrov I, et al. A comparative study of short- and long-TE $^{1}H$ MRS at 3 T for in vivo detection of 2-hydroxyglutarate in brain tumors. NMR Biomed 2013;26:1242-1250 https://doi.org/10.1002/nbm.2943
  18. Natsumeda M, Igarashi H, Nomura T, Ogura R, Tsukamoto Y, Kobayashi T, et al. Accumulation of 2-hydroxyglutarate in gliomas correlates with survival: a study by 3.0-tesla magnetic resonance spectroscopy. Acta Neuropathol Commun 2014;2:158 https://doi.org/10.1186/s40478-014-0158-y
  19. de la Fuente MI, Young RJ, Rubel J, Rosenblum M, Tisnado J, Briggs S, et al. Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma. Neuro Oncol 2016;18:283-290 https://doi.org/10.1093/neuonc/nov307
  20. Lazovic J, Soto H, Piccioni D, Lou JR, Li S, Mirsadraei L, et al. Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation. Neuro Oncol 2012;14:1465-1472 https://doi.org/10.1093/neuonc/nos258
  21. Emir UE, Larkin SJ, de Pennington N, Voets N, Plaha P, Stacey R, et al. Noninvasive quantification of 2-hydroxyglutarate in human gliomas with IDH1 and IDH2 mutations. Cancer Res 2016;76:43-49
  22. Heo H, Kim S, Lee HH, Cho HR, Xu WJ, Lee SH, et al. On the utility of short echo time (TE) single voxel 1H-MRS in noninvasive detection of 2-hydroxyglutarate (2HG); challenges and potential improvement illustrated with animal models using MRUI and LCModel. PLoS One 2016;11:e0147794 https://doi.org/10.1371/journal.pone.0147794
  23. Yen KE, Bittinger MA, Su SM, Fantin VR. Cancer-associated IDH mutations: biomarker and therapeutic opportunities. Oncogene 2010;29:6409-6417 https://doi.org/10.1038/onc.2010.444
  24. Esmaeili M, Vettukattil R, Bathen TF. 2-hydroxyglutarate as a magnetic resonance biomarker for glioma subtyping. Transl Oncol 2013;6:92-98 https://doi.org/10.1593/tlo.12424
  25. Chaumeil MM, Larson PE, Woods SM, Cai L, Eriksson P, Robinson AE, et al. Hyperpolarized [1-13C] glutamate: a metabolic imaging biomarker of IDH1 mutational status in glioma. Cancer Res 2014;74:4247-4257 https://doi.org/10.1158/0008-5472.CAN-14-0680
  26. Tonjes M, Barbus S, Park YJ, Wang W, Schlotter M, Lindroth AM, et al. BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1. Nat Med 2013;19:901-908 https://doi.org/10.1038/nm.3217
  27. Shi J, Sun B, Shi W, Zuo H, Cui D, Ni L, et al. Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation. Tumour Biol 2015;36:655-662 https://doi.org/10.1007/s13277-014-2644-z
  28. Marin-Valencia I, Yang C, Mashimo T, Cho S, Baek H, Yang XL, et al. Analysis of tumor metabolism reveals mitochondrial glucose oxidation in genetically diverse human glioblastomas in the mouse brain in vivo. Cell Metab 2012;15:827-837 https://doi.org/10.1016/j.cmet.2012.05.001
  29. de Graaf RA. In vivo NMR spectroscopy: principles and techniques, 2nd ed. Chichester: John Wiley & Sons, 2007:26-32
  30. Allen PS, Thompson RB, Wilman AH. Metabolite-specific NMR spectroscopy in vivo. NMR Biomed 1997;10:435-444 https://doi.org/10.1002/(SICI)1099-1492(199712)10:8<435::AID-NBM480>3.0.CO;2-D
  31. Govindaraju V, Young K, Maudsley AA. Proton NMR chemical shifts and coupling constants for brain metabolites. NMR Biomed 2000;13:129-153 https://doi.org/10.1002/1099-1492(200005)13:3<129::AID-NBM619>3.0.CO;2-V
  32. Bottomley PA. Selective volume method for performing localized NMR spectroscopy. United States patent US 4480228. 1984 Oct 30
  33. Frahm J, Bruhn H, Gyngell ML, Merboldt KD, Hanicke W, Sauter R. Localized high-resolution proton NMR spectroscopy using stimulated echoes: initial applications to human brain in vivo. Magn Reson Med 1989;9:79-93 https://doi.org/10.1002/mrm.1910090110
  34. Behar KL, Rothman DL, Spencer DD, Petroff OA. Analysis of macromolecule resonances in 1H NMR spectra of human brain. Magn Reson Med 1994;32:294-302 https://doi.org/10.1002/mrm.1910320304
  35. Seeger U, Klose U, Mader I, Grodd W, Nagele T. Parameterized evaluation of macromolecules and lipids in proton MR spectroscopy of brain diseases. Magn Reson Med 2003;49:19-28 https://doi.org/10.1002/mrm.10332
  36. Auer DP, Gossl C, Schirmer T, Czisch M. Improved analysis of 1H-MR spectra in the presence of mobile lipids. Magn Reson Med 2001;46:615-618 https://doi.org/10.1002/mrm.1235
  37. Hofmann L, Slotboom J, Jung B, Maloca P, Boesch C, Kreis R. Quantitative 1H-magnetic resonance spectroscopy of human brain: influence of composition and parameterization of the basis set in linear combination model-fitting. Magn Reson Med 2002;48:440-453 https://doi.org/10.1002/mrm.10246
  38. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 1993;30:672-679 https://doi.org/10.1002/mrm.1910300604
  39. Cudalbu C, Mlynarik V, Gruetter R. Handling macromolecule signals in the quantification of the neurochemical profile. J Alzheimers Dis 2012;31 Suppl 3:S101-S115 https://doi.org/10.3233/JAD-2012-120100
  40. Penner J, Bartha R. Semi-LASER 1 H MR spectroscopy at 7 Tesla in human brain: metabolite quantification incorporating subject-specific macromolecule removal. Magn Reson Med 2015;74:4-12 https://doi.org/10.1002/mrm.25380
  41. Kim H, Thompson RB, Hanstock CC, Allen PS. Variability of metabolite yield using STEAM or PRESS sequences in vivo at 3.0 T, illustrated with myo-inositol. Magn Reson Med 2005;53:760-769 https://doi.org/10.1002/mrm.20434
  42. Thompson RB, Allen PS. A new multiple quantum filter design procedure for use on strongly coupled spin systems found in vivo: its application to glutamate. Magn Reson Med 1998;39:762-771 https://doi.org/10.1002/mrm.1910390514
  43. Sorensen OW, Eich GW, Levitt MH, Bodenhausen G, Ernst RR. Product operator-formalism for the description of NMR pulse experiments. Prog NMR Spectrosc 1983;16:163-192
  44. Young K, Govindaraju V, Soher BJ, Maudsley AA. Automated spectral analysis I: formation of a priori information by spectral simulation. Magn Reson Med 1998;40:812-815 https://doi.org/10.1002/mrm.1910400605
  45. Young K, Soher BJ, Maudsley AA. Automated spectral analysis II: application of wavelet shrinkage for characterization of non-parameterized signals. Magn Reson Med 1998;40:816-821 https://doi.org/10.1002/mrm.1910400606
  46. Thompson RB, Allen PS. Sources of variability in the response of coupled spins to the PRESS sequence and their potential impact on metabolite quantification. Magn Reson Med 1999;41:1162-1169 https://doi.org/10.1002/(SICI)1522-2594(199906)41:6<1162::AID-MRM12>3.0.CO;2-N
  47. Li Y, Srinivasan R, Ratiney H, Lu Y, Chang SM, Nelson SJ. Comparison of T(1) and T(2) metabolite relaxation times in glioma and normal brain at 3T. J Magn Reson Imaging 2008;28:342-350 https://doi.org/10.1002/jmri.21453
  48. Lange T, Dydak U, Roberts TP, Rowley HA, Bjeljac M, Boesiger P. Pitfalls in lactate measurements at 3T. AJNR Am J Neuroradiol 2006;27:895-901
  49. Mescher M, Merkle H, Kirsch J, Garwood M, Gruetter R. Simultaneous in vivo spectral editing and water suppression. NMR Biomed 1998;11:266-272 https://doi.org/10.1002/(SICI)1099-1492(199810)11:6<266::AID-NBM530>3.0.CO;2-J
  50. Rothman DL, Behar KL, Hetherington HP, Shulman RG. Homonuclear 1H double-resonance difference spectroscopy of the rat brain in vivo. Proc Natl Acad Sci U S A 1984;81:6330-6334 https://doi.org/10.1073/pnas.81.20.6330
  51. Hetherington HP, Avison MJ, Shulman RG. 1H homonuclear editing of rat brain using semiselective pulses. Proc Natl Acad Sci U S A 1985;82:3115-3118 https://doi.org/10.1073/pnas.82.10.3115
  52. Ernst RR, Bodenhausen G, Wokaun A. Principles of nuclear magnetic resonance in one and two dimensions. Oxford: Oxford University Press, 1987:400-427
  53. Aue WP, Bartholdi E, Ernst RR. Two-dimensional spectroscopy. Application to nuclear magnetic resonance. J Chem Phys 1976;64:2229-2246 https://doi.org/10.1063/1.432450
  54. Provencher SW. LCModel & LCMgui user's manual. Web site. http://s-provencher.com/pub/LCModel/manual/manual.pdf. Accessed January 5, 2016
  55. Opstad KS, Bell BA, Griffiths JR, Howe FA. Toward accurate quantification of metabolites, lipids, and macromolecules in HRMAS spectra of human brain tumor biopsies using LCModel. Magn Reson Med 2008;60:1237-1242 https://doi.org/10.1002/mrm.21496
  56. Naressi A, Couturier C, Devos JM, Janssen M, Mangeat C, de Beer R, et al. Java-based graphical user interface for the MRUI quantitation package. MAGMA 2001;12:141-152 https://doi.org/10.1007/BF02668096
  57. Cavassila S, Deval S, Huegen C, van Ormondt D, Graveron-Demilly D. Cramer-Rao bounds: an evaluation tool for quantitation. NMR Biomed 2001;14:278-283 https://doi.org/10.1002/nbm.701
  58. Reitman ZJ, Jin G, Karoly ED, Spasojevic I, Yang J, Kinzler KW, et al. Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proc Natl Acad Sci U S A 2011;108:3270-3275 https://doi.org/10.1073/pnas.1019393108
  59. Terunuma A, Putluri N, Mishra P, Mathe EA, Dorsey TH, Yi M, et al. MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. J Clin Invest 2014;124:398-412 https://doi.org/10.1172/JCI71180
  60. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009;361:1058-1066 https://doi.org/10.1056/NEJMoa0903840
  61. Struys EA, Salomons GS, Achouri Y, Van Schaftingen E, Grosso S, Craigen WJ, et al. Mutations in the D-2-hydroxyglutarate dehydrogenase gene cause D-2-hydroxyglutaric aciduria. Am J Hum Genet 2005;76:358-360 https://doi.org/10.1086/427890
  62. Green A, Beer P. Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. N Engl J Med 2010;362:369-370 https://doi.org/10.1056/NEJMc0910063
  63. Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010;17:225-234 https://doi.org/10.1016/j.ccr.2010.01.020
  64. Kang MR, Kim MS, Oh JE, Kim YR, Song SY, Seo SI, et al. Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int J Cancer 2009;125:353-355 https://doi.org/10.1002/ijc.24379
  65. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006;314:268-274 https://doi.org/10.1126/science.1133427
  66. Lopez GY, Reitman ZJ, Solomon D, Waldman T, Bigner DD, McLendon RE, et al. IDH1(R132) mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain. Biochem Biophys Res Commun 2010;398:585-587 https://doi.org/10.1016/j.bbrc.2010.06.125

Cited by

  1. Magnetic Resonance Spectroscopy for Detection of 2-Hydroxyglutarate as a Biomarker for IDH Mutation in Gliomas vol.7, pp.2, 2017, https://doi.org/10.3390/metabo7020029
  2. T2–FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project vol.23, pp.20, 2016, https://doi.org/10.1158/1078-0432.ccr-17-0560
  3. Highly specific determination of IDH status using edited in vivo magnetic resonance spectroscopy vol.20, pp.7, 2016, https://doi.org/10.1093/neuonc/nox214
  4. Imaging in low-grade glioma: a guide for neurologists vol.18, pp.1, 2016, https://doi.org/10.1136/practneurol-2017-001686
  5. Clinical applications of in vivo magnetic resonance spectroscopy in oncology vol.63, pp.21, 2018, https://doi.org/10.1088/1361-6560/aae61e
  6. PI3K/mTOR inhibition of IDH1 mutant glioma leads to reduced 2HG production that is associated with increased survival vol.9, pp.None, 2019, https://doi.org/10.1038/s41598-019-47021-x
  7. Fitting algorithms and baseline correction influence the results of non‐invasive in vivo quantitation of 2‐hydroxyglutarate with 1H‐MRS vol.32, pp.1, 2016, https://doi.org/10.1002/nbm.4027
  8. Prediction of IDH Status Through MRI Features and Enlightened Reflection on the Delineation of Target Volume in Low-Grade Gliomas vol.18, pp.None, 2016, https://doi.org/10.1177/1533033819877167
  9. False-Positive Measurement at 2-Hydroxyglutarate MR Spectroscopy in Isocitrate Dehydrogenase Wild-Type Glioblastoma: A Multifactorial Analysis vol.291, pp.3, 2016, https://doi.org/10.1148/radiol.2019182200